

24th January, 2019

То,	То,
Department of Corporate Services	The Manager,
BSE Ltd.	Listing Department,
Phiroze Jeejeebhoy Towers,	National Stock Exchange of India Ltd.
Dalal Street,	"Exchange Plaza", C-1, Block G,
Mumbai – 400 001.	Bandra-Kurla Complex,
	Bandra (E), Mumbai – 400 051.
Ref.: Scrip Code No. : 540701	Ref. : (i) Symbol – DCAL (ii) Series – EQ

SUB: INVESTORS PRESENTATION ON UNAUDITED FINANCIAL RESULT - REGULATION: 30

Dear Sir,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, kindly find enclosed herewith Presentation on financial result for the quarter ended 31st December, 2018 to be made to Analyst and Investors.

The aforesaid presentation is also being hosted on the website of the Company, <u>www.dishmangroup.com</u> in accordance with the Regulation 46 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Kindly take the same on your record.

Thanking You,

Yours faithfully, For, Dishman Garbogen Ameis Limited Carbogen Shrima Dave Ahmedabad **Company Secretary** Encl.: As above

Dishman Carbogen Amcis Limited (Formerly Carbogen Amcis (I) Ltd)

DISHMAN CORPORATE HOUSE Iscon-Bopal Road, Ambli, Ahmedabad-380 058. (India) Phone : +91 (0) 2717 420100 / 420124 E-mail : dcal@dishmangroup.com Website : www.dishmangroup.com Regd. Off.: Bhadra-Raj Chambers, Swastik Cross Road, Navrangpura, Ahmedabad-380 009. (India) Phone : +91 (0) 79 26443053 / 26445807 / 26560089 Fax : +91 (0) 79 26420198

Government Recognised Export House CIN No. : L74900GJ2007PLC051338



ENERGISE YOUR SCIENCE FOR LIFE

DISHMAN CARBOGEN AMCIS LIMITED

Q3 & 9M FY19 RESULTS UPDATE JANUARY 2019 This presentation and the following discussion may contain "forward looking statements" by Dishman Carbogen Amcis Limited ('Dishman' or the 'Company') that are not historical in nature. These forward looking statements, which may include statements relating to future results of operations, financial condition, business prospects, plans and objectives, are based on the current beliefs, assumptions, expectations, estimates, and projections of the management of Dishman about the business, industry and markets in which Dishman operates.


These statements are not guarantees of future performance, and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond Dishman's control and difficult to predict, that could cause actual results, performance or achievements to differ materially from those in the forward looking statements. Such statements are not, and should not be construed, as a representation as to future performance or achievements of Dishman.

In particular, such statements should not be regarded as a projection of future performance of Dishman. It should be noted that the actual performance or achievements of Dishman may vary significantly from such statements.



DISCUSSION SUMMARY

- ✤ Q3 & 9M FY19 RESULTS UPDATE
- INDUSTRY OVERVIEW
- ✤ COMPANY OVERVIEW




Q3 & 9M FY19 RESULTS UPDATE






9M FY19 RESULTS HIGHLIGHTS



* EBITDA excluding other income

[#] PBT is adjusted to include the additional goodwill amortization of Rs. 663.3 mn in 9M FY18 and 9M FY19.




 Cash PAT = Adjusted PAT + (Depreciation – additional goodwill amortization), adjusted for merger impact Adjusted PAT = Adjusted PBT – Normalized tax rate of 30%



In Rs Mn

Q3 FY19 RESULTS HIGHLIGHTS



 EBITDA & EBITDA MARGIN *

 26.4%
 27.7%

 1,212
 1,327

 0
 1,327

 Q3 FY18
 Q3 FY19

 CASH PAT @ & CASH EPS

 5.9
 6.4

 960
 1,032

Q3 FY18

© Cash PAT = Adjusted PAT + (Depreciation – additional goodwill amortization), adjusted for merger impact Adjusted PAT = Adjusted PBT – Normalized tax rate of 30%

Q3 FY19

🗟 dishman 🛛 🌮 🕬

In Rs Mn

* EBITDA excluding other income

[#] PBT is adjusted to include the additional goodwill amortization of Rs. 221.1 mn in Q3 FY18 and Q3 FY19.

CONSOLIDATED P&L STATEMENT

Particulars (Rs. Mn.)	Q3 FY19	Q3 FY18	YoY %	Q2 FY19	QoQ %	9M FY19	9M FY18	YoY %
Revenues from Operations	4,273.9	4,309.1	-0.8%	4,324.1	-1.2%	13,085.2	12,001.6	9.0%
Other Operating Income	515.5	289.1	78.3%	153.0	236.9%	1,003.6	431.4	132.6%
Total Revenues	4,789.4	4,598.2	4.2%	4,477.1	7.0%	14,088.8	12,433.0	13.3%
COGS	719.6	1,034.2	-30.4%	690.9	4.2%	2,512.8	2,303.0	9.1%
Employee Expenses	1,783.9	1,584.4	12.6%	1,596.9	11.7%	5,101.9	4,536.8	12.5%
Other Expenses	958.5	767.6	24.9%	903.4	6.1%	2,648.9	2,351.1	12.7%
EBITDA	1,327.4	1,212.0	9.5%	1,285.9	3.2%	3,825.2	3,242.1	18.0%
EBITDA Margin %	27.7%	26.4%	136bps	28.7%	-101bps	27.2%	26.1%	107bps
Other Income	133.7	146.2	-8.5%	149.9	-10.8%	340.2	301.9	12.7%
Depreciation & Amortization	576.9	549.6	5.0%	575.0	0.3%	1,692.9	1,609.4	5.2%
Finance Cost (Incl. Forex Impact)	139.6	128.0	9.1%	152.4	-8.4%	439.0	375.5	16.9%
Reported PBT	744.6	680.6	9.4%	708.4	5.1%	2,033.5	1,559.1	30.4%
Tax Expense	230.9	260.6	-11.4%	268.3	-13.9%	683.6	525.0	30.2%
Current Tax	152.0	215.4	-29.4%	198.5	-23.4%	514.0	397.2	29.4%
Deferred Tax	78.9	45.2	74.6%	69.8	13.0%	169.6	127.8	32.7%
% Tax Rate	31.0%	38.3%	-	37.9%	-	33.6%	33.7%	-
Reported PAT	513.7	420.0	22.3%	440.1	16.7%	1,349.9	1,034.1	30.5%
PAT Margin %	10.7%	9.1%	159bps	9.8%	90bps	9.6%	8.3%	126bps
EPS	3.2	2.6	22.3%	2.7	16.5%	8.4	6.4	30.4%



Q3 & 9M FY19 SEGMENT-WISE REVENUE ANALYSIS

In Rs Mn

Revenues – Segment wise Breakup	Q3 FY19	Q3 FY18	ΥοΥ%	9M FY19	9M FY18	ΥοΥ%
CRAMS						
CRAMS – India	765.0	433.2	76.6%	2,100.8	1,411.0	48.9%
CRAMS – CAAG+RIOM*	2,368.4	2,682.6	-11.7%	7,265.0	7,348.5	-1.1%
CRAMS – UK	206.5	186.7	10.6%	622.5	380.3	63.7%
CRAMS Total	3,339.9	3,302.6	1.1%	9,988.3	9,139.8	9.3%
Marketable Molecules						
Carbogen Amcis BV**	671.4	494.1	35.9%	1,899.2	1,468.5	29.3%
Others	262.6	512.4	-48.7%	1,197.6	1,393.3	-14.0%
Marketable Molecules Total	934.0	1,006.5	-7.2%	3,096.8	2,861.8	8.2%
Total	4,273.9	4,309.1	-0.8%	13,085.1	12,001.6	9.0%


* CRAMS - CAAG+RIOM includes DCAL's Switzerland (Carbogen Amcis AG) and France (Riom) facilities

** Carbogen Amcis BV is Dishman Netherlands

Others includes Carbogen Amcis Shanghai



9M FY19 SEGMENT-WISE REVENUE BREAK-UP



* CRAMS – CAAG+RIOM includes DCAL's Switzerland (Carbogen Amcis AG) and France (Riom) facilities

** Carbogen Amcis BV is Dishman Netherlands

Others includes Carbogen Amcis Shanghai



Q3 & 9M FY19 SEGMENT-WISE MARGIN ANALYSIS

EBITDA Margin % – Segment wise	Q3 FY19	Q3 FY18	9M FY19	9M FY18
CRAMS				
CRAMS – India	59.6%	57.5%	58.3%	53.5%
CRAMS – CAAG+RIOM*	20.3%	21.3%	20.4%	20.5%
CRAMS – UK	32.2%	29.2%	26.1%	25.0%
Marketable Molecules				
Carbogen Amcis BV**	41.4%	40.8%	42.7%	38.6%
Others#	17.8%	26.4%	12.1%	22.8%

* CRAMS - CAAG+RIOM includes DCAL's Switzerland (Carbogen Amcis AG) and France (Riom) facilities

** Carbogen Amcis BV is Dishman Netherlands

Others includes Carbogen Amcis Shanghai



Q3 & 9M FY19 RESULTS HIGHLIGHTS

□ Total Revenues – Q3 FY 2019 Rs 4,789.4 mn (+4.2% YoY); 9M FY 2019 Rs 14,088.8 mn (+13.3% YoY).

- Total CRAMS revenues in Q3 FY 2019 increased by 1.1% YoY to Rs 3,339.9 mn driven by CRAMS India. Total CRAMS revenues in 9M FY 2019 grew by 9.3% YoY driven by growth in CRAMS India and UK Segments. Carbogen Amcis AG was stable.
- CRAMS India Q3 and 9M FY 2019 YoY revenue growth of 76.6% and 48.9% respectively, due to higher commercial orders.
- CRAMS Carbogen Amcis AG Q3 FY 2019 revenues declined by 11.7% YoY due to customers' commercial order requirements to be supplied in Q4 FY 2019. Higher proportion of development work undertaken in this quarter. Marginal decline of 1.1% YoY in 9M FY 2019 revenues.
- CRAMS UK 9M FY 2019 revenue growth of 63.7% YoY due to strong execution of Non-GMP commercial orders.
- Carbogen Amcis BV Q3 and 9M FY 2019 YoY revenue growth of 35.9% and 29.3% respectively, due to increase in sale of Vitamin D analogues.
- Others Q3 FY 2019 revenues declined by 48.7% YoY due to reduced focus on low-margin products.


EBITDA Margin – Q3 FY 2019 at 27.7% (+136 bps YoY); 9M FY19 at 27.2% (+107 bps YoY).

- Q3 FY 2019 EBITDA margin improvement driven by higher revenue contribution from high-margin commercial orders and Vitamin D Analogues.
- Other expenses for the quarter increased by 24.9% YoY mainly due to the impact of foreign currency translation and increase in repairs & maintenance cost.



IMPROVING MARGIN PROFILE ACROSS KEY SEGMENTS

Segment-Wise EBITDA Margin Trend



CARBOGEN AMCIS



1.54.1

A STATE AND

INDUSTRY OVERVIEW



GLOBAL SPENDING ON MEDICINE

As per BRC Report, Contract Research Outsourcing (CRO) Market to reach \$44.4bn by 2021


Outlook of Leading Therapy Areas Spending and Growth, Constant US \$ Bn					
Therapy Areas	Spending 2017	2012-17 CAGR	Spending 2022	2017-22 CAGR	
Oncology	133.0	11.8%	180–200	10-13%	
Cardiovascular	40.6	-1.8%	36-44	(-2%) – 1%	
Pain	76.1	5.7%	80-95	2-5%	
Diabetes	72.2	16.9%	105-115	8-11%	
Respiratory	38.5	4.8%	40-50	2-5%	
Antibiotics and Vaccines	38.3	3.2%	40-48	1-4%	
Autoimmune	47.5	16.8%	65-75	7-10%	
Mental Health	36.1	-2.6%	32-38	(-2%) – 1%	
Antivirals EX – HIV	23.8	25.0%	16-20	(-7%) – (-4%)	
HIV	26.7	11.5%	32-40	5-8%	
All Others	368.3	5.1%	445-460	3-6%	

- Oncology is expected to be the most critical therapeutic segment driving the global spend on medicine in future.
- Growth in Oncology is led by a constant upsurge of the immune-oncology treatment which drastically improves outcomes and resistance for patients.
- Global Spend on Medicine by Developed Markets is estimated to be \$915-945bn by 2022, growing at 2-5% CAGR. The 2022 estimate for Pharmerging Markets is \$345-375bn, growing at 6-9% CAGR.
- Oncology as a therapeutic segment is a key focus area for Dishman.
- Currently, around 50% of Dishman's annual revenues come from Oncology therapeutic segment.

🗟 dishman

Source: IQVIA – 2018 and Beyond – Outlook and Turning Points, March 2018; Global Oncology Trends, May 2018 Note: Includes 8 developed and 6 pharmerging countries: U.S., France, Germany, Italy, Spain, UK, Japan, Canada, China, Brazil, Russia, India, Turkey, Mexico

GLOBAL MEDICINES IN LATE STAGE DEVELOPMENT




- Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies.
- Around 29% of the Phase II / III clinical trials are in the Oncology segment.
- Oncology (cancer treatment) requires highly potent drugs which are highly effective at much smaller dosages and have the ability to target only the diseased cells.
- Dishman's High Potency API (HIPO) facility at Bavla, India is the largest facility in Asia and one of its kind facility in the World.
- Currently, Dishman has 25+ molecules in early phase III and 15-16 molecules in late phase III. Out of these, around 50% molecules are in Oncology segment.



Source: IQVIA Market Prognosis, Sep 2017; IQVIA Institute, Oct 2017

GLOBAL ONCOLOGY MEDICINE PIPELINE



- > 710 Molecules in late-stage development and 700+ companies with late-stage oncology drugs.
- ➤ Top companies with combined sales of \$10bn+ have ~40% of their product pipeline in oncology.
- > 455 smaller companies with 90%+ product pipeline in oncology, are involved in 1,692 product indications which represent 45% of overall cancer pipeline.

🗟 dishman

Source: IQVIA R&D Intelligence, Dec 2017; Global Oncology Trends, May 2018





COMPANY OVERVIEW

Ne II.

Ta.



BRIEF PROFILE



BUSINESS OVERVIEW

- Integrated CRAMS company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing.
- Global presence with manufacturing sites in Switzerland, UK, France, Netherlands, India and China.
- Comprehensive product offerings APIs, High Potent APIs, Intermediates, Phase Transfer Catalysts, Vitamin D Analogues, Cholesterol, Lanolin-related products, Antiseptic and Disinfectant formulations.



KEY STRENGTHS

- Preferred global outsourcing partner with capabilities across the entire CRAMS value chain.
- Strong chemistry skills.
- Upfront investment of more than Rs 10,000 Mn in large scale multi-purpose manufacturing capacities.
- The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Dishman is at forefront to gain from the high margin HIPO opportunity in the Oncology space.


FINANCIAL OVERVIEW

- Consolidated Revenues, EBITDA and Adj. PAT of Rs 16,948 Mn, Rs 4,454 Mn and Rs 2,235 Mn in FY18.
- Strong balance sheet with D:E ratio of 0.21x as on Mar-18.
- Improving profitability and return ratios over FY13 to FY18
 - EBITDA margin 22.8% to 26.3%
 - PAT margin 7.9% to 13.2%
 - ROCE 11.1% to 13.1% *
 - ROE 10.2% to 15.2% #

* FY18 ROE = Adj. PAT / Average (Equity – Goodwill), Adj. PAT = Rs 2,235 Mn (adjusted to exclude merger impact) * FY18 ROCE = Adj. EBIT / Average (Equity – Goodwill + Debt), Adj. EBIT = EBIT + Rs 884.5 Mn of additional goodwill amortization on account of merger



MANUFACTURING FACILITES – ROBUST R&D CAPABILITIES



Superior Chemistry Skills & Capabilities

- 28 dedicated R&D labs with multiple-shift R&D operations, including HIPO labs
- 25 multi-purpose facilities at Bavla, Naroda, Manchester, Switzerland, Netherlands and Shanghai
- 1 dedicated production facility for APIs and Intermediates at Bavla
- 7,500 m² floor space of R&D at Switzerland, Manchester and Bavla
- Asia's largest HIPO facility at Bavla, India
- 750 m³ of reactor capacity at Bavla, 230 m³ at Naroda and 63 m³ at Shanghai





PREFERRED GLOBAL OUTSOURCING PARTNER



Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product launch stage

Drug Lifecycle Management

- Preclinical to commercial manufacturing capabilities.
- Ensures seamless process & technology transfer from lab to plant.
- Single partner for R&D, process development and commercial production.

20

Strong R&D Capabilities

 Globally, Dishman group has ~550 scientists, with 50+ doctorates as senior scientists.

Close Proximity to Clients


- Local representation, local support in all major markets
- Front end via CA with access to more than 200 established customer relationships of CA.
- Trust & Confidence of customers for entire drug lifecycle engagement.

Large Scale Mfg. Capacity

- Dedicated USFDA inspected production facilities.
- Asia's largest HIPO facility in Bavla.
- Large capacities provide competitive edge to win big long-term contracts

🗟 dishmani

INTEGRATED CRAMS PLAYER



Carbogen Amcis (CA) Strong Research Capabilities

- Focus is on supporting the development process from bench to market.
- Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use.

Dishman India Strong Manufacturing Capabilities

- Large dedicated R&D center with multiple shift R&D operations (India)
- Multi-purpose and dedicated production facilities for APIs, intermediates (India, Europe and China)
- Dedicated API manufacturing capacities (India, China)


🗟 dishman



CUTTING-EDGE HIPO CAPABILITIES

World Class HIPO capabilities

- Facilities range from laboratory scale for process research and development to large scale manufacturing on **8,000** L scale, with an ability to handle the highest category IV compounds (high toxicity levels).
- State-of-the-art containment services, with all cGMP compliant facilities with an ability to operate for preclinical testing, clinical trials and commercial use.
- The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo-lab and full scale manufacturing units to cater to both small volume and large volume orders





CORPORATE RESTRUCTURING

SCHEME OF ARRANGEMENT & AMALGAMATION

- The Board Of Directors approved the Scheme of Arrangement and Amalgamation on 24th February 2016, which involves merger of Dishman Pharmaceuticals and Chemicals Limited ('DPCL') and Dishman Care Limited ('DCL') with Carbogen Amcis (India) Limited ('CAIL').
- Post the merger, DPCL will now be known as Dishman Carbogen Amcis (India) Limited ('DCAL').

IMPACT OF MERGER

- The amalgamation has been accounted under the "Purchase Method" as per AS14.
- Accordingly the assets and liabilities of DPCL and DCL have been recorded at fair value as on Appointed Date of 1st January 2015.
- The purchase consideration of Rs. 48.1 Bn has resulted in goodwill of Rs. 13.3 Bn which represents the excess consideration payable over the net assets.
- This goodwill will be amortized over the period of 15 years starting from the Appointed Date of 1st January 2015.

EXCLUDING MERGER IMPACT

Particulars (Rs Mn)	FY18	FY17	YoY %
Total Revenues	16,947.9	17,136.9	-1.1%
Adjusted PBT #	3,192.5	3,045.4	4.8%
Tax Expense	957.8	913.7	4.8%
Adjusted PAT after MI, share of associates	2,234.8	2,131.8	4.8%

Key Benefits:

- Strengthened Balance Sheet and Consolidation of operating entities for improved operational control.
- Amortisation of goodwill will lead to significant tax savings over coming 15 years


🗟 dishman

* PBT is adjusted to exclude the additional goodwill amortization of Rs. 884.6 mn in FY18 and FY17 on account of merger

SHAREHOLDING STRUCTURE



% Shareholding as on 31 Dec 2018



Market Data	As on 23 Jan 2019 (BSE)
Market capitalization (Rs Mn)	35,353
Price (Rs.)	219.1
No. of shares outstanding (Mn)	161.4
Face Value (Rs.)	2.0
52 week High-Low (Rs.)	377.1–214.1

Key Institutional Investors as on 31 Dec 2018	% Holding
TATA MF	3.16%
IDFC MF	2.48%
ICICI Prudential MF	2.41%
Aditya Birla SunLife MF	1.34%
Government Pension Fund Global	1.32%
L&T MF	1.25%



ENERGISE YOUR SCIENCEFOR LIFE

FOR FURTHER QUERIES:

🥪dishman

Mr. Harshil Dalal Senior Vice President – Accounts & Finance Email: harshil.dalal@dishmangroup.com

DICKENSON

Mr. Arun Prakash / Nilesh Dalvi IR Consultants <u>Contact:</u> +91 9920993892 / +91 9819289131

Email: arun.prakash@dickensonir.com nilesh.dalvi@dickensonir.com